Die schöne PRANA

Kosmonova buran

Datum Erster Hoch Tief Schluss     Stücke Volumen
  27.11.13      4,73      4,80§4,62 4,70 $ 136.774 0,64 M

GrB

Datum Erster Hoch Tief Schluss     Stücke Volumen
  29.11.13      4,74      4,96§4,725 4,91 $ 116.747 0,57 M

GrB

  15:42:20§5,1899 $
       100          §
  15:42:20§5,19 $
       100          §
  15:42:20§5,1899 $
       100          §
  15:42:20§5,19 $
       200          §
  15:42:20§5,1899 $
       100          §
  15:42:20§5,19 $
       100          §
  15:42:20§5,1899 $
       100          §
  15:42:20§5,1898 $
       800          §
  15:42:20§5,1899 $
       800          §
  15:42:20§5,19 $
       100          §
  15:42:20§5,1899 $
     1.950          §
  15:42:20§5,19 $
     1.850          §
  15:42:20§5,1899 $
       600          §
  15:41:35§5,1501 $
     1.000          §
  15:41:02§5,15 $
     1.000          §
  15:40:05§5,1799 $
       100          §
  15:40:05§5,19 $
     1.000          §
  15:40:05§5,18 $
       100          §
  15:40:04§5,179 $
     2.900          §
  15:39:01§5,1899 $
       120          §
  15:38:43§5,19 $
     1.000          §
  15:38:26§5,1401 $
       400          §
  15:38:08§5,19 $
       700          §
  15:37:52§5,2155 $
     2.700          §
  15:37:52§5,21 $
     1.500          §
  15:37:52§5,2065 $
     1.500          §
  15:37:52§5,21 $
       800          §
  15:37:52§5,2065 $
       800          §
  15:37:34§5,2099 $
     1.200          §
  15:37:23§5,1909 $
     1.000          §
  15:36:52§5,21 $
       300          §
  15:36:38§5,2299 $
       200          §
  15:36:17§5,1999 $
     1.000          §
  15:36:17§5,20 $
     3.000          §
  15:36:00§5,17 $
       129          §
  15:35:58§5,15 $
     3.000          §
  15:35:49§5,15 $
       500          §
  15:35:45§5,13 $
       800          §
  15:35:42§5,13 $
     1.000          §
  15:35:30§5,13 $
       100          §
  15:35:30§5,12 $
       142          §
  15:35:22§5,11 $
       100          §
  15:35:16§5,12 $
       100          §
  15:35:15§5,12 $
       329          §
  15:35:00§5,11 $
       100          §
  15:35:00§5,12 $
       329          §
  15:34:45§5,11 $
       100          §
  15:34:45§5,12 $
       400          §
  15:34:45§5,106 $
       100          §
  15:34:31§5,11 $
     1.000          §
  15:34:30§5,11 $
       329          §
  15:34:27§5,1099 $
     1.500          §
  15:34:19§5,1099 $
       750          §
  15:34:19§5,11 $
       150          §
  15:34:19§5,1099 $
       250          §
  15:34:19§5,11 $
       100          §
  15:33:30§5,10 $
       100          §
  15:32:56§5,0601 $
     1.000          §
  15:32:46§5,1199 $
     1.000          §
  15:32:45§5,12 $
     4.600          §
  15:32:44§5,12 $
     3.000          §
  15:32:44§5,09 $
       400          §
  15:32:42§5,07 $
       412          §
  15:32:16§5,06 $
       100          §
  15:31:26§5,0417 $
     1.500          §
  15:30:55§5,04 $
       200          §
  15:30:45§5,069 $
       100          §
  15:30:40§5,01 $
       200          §
  15:30:00§5,00 $
14.825

GrB

RTK 5,65  $ SKP +15,07 EK 4,91 $ last shares 100 full realtime 1.175.019 peak 5,73

buran und MfG und danke und weitermachen

Datum Erster Hoch Tief Schluss     Stücke Volumen
  02.12.13      5,00      5,73§5,00 5,72 $ 1.353.036 7,46 M

GrB

5.72 Up 0.81(16.50%) Dec 2, 4:00PM EST|After Hours : 5.60 Down 0.12 (2.10%) Dec 2, 7:07PM EST

Prev Close: 4.91
     Open:      5.00§
      Bid:§5.11 x 200
      Ask:§5.88 x 600
1y Target Est: 6.00
     Beta:§0.27
Next Earnings Date: N/A
Day's Range: 5.00 - 5.73
52wk Range: 2.03 - 6.50
   Volume:§1,360,362
Avg Vol (3m): 656,792
Market Cap: 222.89M
P/E (ttm): N/A
EPS (ttm): -0.24
Div & Yield: N/A (N/A)
finance.yahoo.com/q?s=PRAN&ql=1

is a world leader in addressing the role of biological metals in human disease.

Abundant scientific evidence suggests that many age-related conditions result from pathological interactions between selected metals and target proteins. The company has developed a proprietary library of chemical compounds that target these interactions, preventing protein aggregation and corruption.

The mission of the company is to develop disease modifying therapeutics for the treatment of common neurological disorders, with a focus upon Alzheimer's, Parkinson's and Huntington's diseases. Other potential applications for this platform technology include specific cancers and Age-related Macular Degeneration.
www.pranabio.com/

focused on the research and development of treatments for Alzheimer's Disease and other major neurodegenerative disorders. Researchers at prominent international institutions including The University of Melbourne, The Mental Health Research Institute (Melbourne) and Massachusetts General Hospital, a teaching hospital of Harvard Medical School, contributed to the discovery of Prana's technology.

The Company was incorporated in 1997 in Melbourne, Australia and listed on the on the Australian Stock Exchange in 2000 (ASX: PBT) and NASDAQ in 2002 (Nasdaq: PRAN).
www.pranabio.com/default.asp?contentID=596

www.pranabio.com/default.asp?contentID=662 GrB

Financial Year 2013
Form 6K

Financial Year 2012
Appendix 4D
Form 6K

Financial Year 2011
Appendix 4D
Form 6K

Financial Year 2010
Appendix 4D
Form 6K

Financial Year 2009
Appendix 4D
Form 6K

Financial Year 2008
Appendix 4D
Form 6K

Financial Year 2007
Appendix 4D
Form 6K

Financial Year 2006
Appendix 4D
Form 6K

Financial Year 2005
Appendix 4D
Form 6K

Financial Year 2004
Appendix 4D
www.pranabio.com/default.asp?contentID=663

Financial Year 2014
Appendix 4C September 2013

Financial Year 2013
Appendix 4C June 2013
Appendix 4C March 2013
Appendix 4C December 2012
Appendix 4C September 2012

Financial Year 2012
Appendix 4C June 2012
Appendix 4C March 2012  
Appendix 4C December 2011
Appendix 4C September 2011

Financial Year 2011
Appendix 4C June 2011
Appendix 4C March 2011
Appendix 4C December 2010
Appendix 4C September 2010

Financial Year 2010
Appendix 4C June 2010
Appendix 4C March 2010
Appendix 4C December 2009
Appendix 4C September 2009

Financial Year 2009
Appendix 4C June 2009
Appendix 4C March 2009
Appendix 4C December 2008
Appendix 4C September 2008

Financial Year 2008
Appendix 4C June 2008
Appendic 4C March 2008
Appendix4C December 2007
Appendix 4C September 2007

Financial Year 2007
Appendix 4C June 2007
Appendix 4C March 2007
Appendix 4C December 2006
Appendix 4C September 2006

Financial Year 2006
Appendix 4C June 2006
Appendix 4C March 2006
Appendix 4C December 2005
Appendix 4C September 2005

Financial Year 2005
Appendix 4C June 2005
Appendix 4C March 2005
Appendix 4C December 2004
Appendix 4C September 2004

Financial Year 2004
Appendix 4C June 2004
Appendix 4C March 2004
Appendix 4C December 2003
Appendix 4C September 2003

Financial Year 2003
Appendix 4C June 2003
Appendix 4C March 2003
Appendix 4C December 2002

Financial Year 2002
Appendix 4C March 2002
Appendix 4C December 2001
Appendix 4C September 2001

Financial Year 2001
Appendix 4C June 2001
www.pranabio.com/default.asp?contentID=664

www.pranabio.com/default.asp?contentID=681 GrB

www.pranabio.com/default.asp?contentID=630 GrB

www.pranabio.com/default.asp?contentID=658 GrB

RESULTS OF ANNUAL GENERAL MEETING


Thursday, 28th November 2013

The Company wishes to advise that all resolutions contained in the Notice of Meeting were carried on a
show of hands.

In accordance with Listing rule 3.13.2 and Section 251AA(1) of the Corporations Act 2001, the following
information is provided in relation to the resolutions considered by Members of the Company at the Annual
General Meeting held today.



* The Chairman voted undirected proxies in his control in favour of all resolutions.


On behalf of the Board


Richard Revelins
Company Secretary
Prana Biotechnology Limited
www.pranabio.com/downloads/...%202013%20Results%20of%20AGM.pdf

www.pranabio.com/default.asp?contentID=629 GrB

Prana Provides Update on IMAGINE Trial and Extension Trial for
Alzheimer’s Disease:

Melbourne – Monday 18th November, 2013: Prana Biotechnology (NASDAQ:PRAN;
ASX:PBT) has today provided an update on the IMAGINE Phase 2 trial for Alzheimer’s
Disease and is pleased to report that 29 patients of the 42 patients originally enrolled into the
trial have now completed treatment.

The IMAGINE trial is a 12-month double-blind Phase 2 clinical trial of PBT2 in Alzheimer’s
patients. Patients who have completed the full 12-month term of the IMAGINE trial are
eligible for participation in an open-label Extension study. All participants in the Extension
study will receive a 250mg once daily oral dose of PBT2 for an additional 12 months.

So far, 24 patients (of a possible 29) have continued on to the Extension trial, with a further
patient currently being screened.

The company can also report that the Data Safety Monitoring Board (DSMB) has met for the
fifth and final time and, consistent with all previous safety reviews, has made no
recommendations to review or alter the original IMAGINE trial protocol.

The results of the IMAGINE Phase 2 trial are expected in March 2014.


About Prana Biotechnology Limited
Prana Biotechnology was established to commercialise research into age-related
neurodegenerative disorders. The Company was incorporated in 1997 and listed on the
Australian Securities Exchange in March 2000 and listed on NASDAQ in September 2002.
Researchers at prominent international institutions including The University of Melbourne,
The Mental Health Research Institute (Melbourne) and Massachusetts General Hospital, a
teaching hospital of Harvard Medical School, contributed to the discovery of Prana’s
technology.

For further information please visit the Company’s web site at www.pranabio.com.
www.pranabio.com/downloads/...0on%20AD%20Clinical%20Trials.pdf

For further information please visit the Company’s web site at www.pranabio.com. Page 2 of 2
Forward Looking Statements
This press release contains "forward-looking statements" within the meaning of section 27A of the
Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934. The Company has
tried to identify such forward-looking statements by use of such words as "expects," "intends,"
"hopes," "anticipates," "believes," "could," "may," "evidences" and "estimates," and other similar
expressions, but these words are not the exclusive means of identifying such statements. Such
statements include, but are not limited to any statements relating to the Company's drug development
program, including, but not limited to the initiation, progress and outcomes of clinical trials of the
Company's drug development program, including, but not limited to, PBT2, and any other statements
that are not historical facts. Such statements involve risks and uncertainties, including, but not limited
to, those risks and uncertainties relating to the difficulties or delays in financing, development, testing,
regulatory approval, production and marketing of the Company’s drug components, including, but not
limited to, PBT2, the ability of the Company to procure additional future sources of financing,
unexpected adverse side effects or inadequate therapeutic efficacy of the Company's drug
compounds, including, but not limited to, PBT2, that could slow or prevent products coming to market,
the uncertainty of patent protection for the Company's intellectual property or trade secrets, including,
but not limited to, the intellectual property relating to PBT2, and other risks detailed from time to time
in the filings the Company makes with Securities and Exchange Commission including its annual
reports on Form 20-F and its reports on Form 6-K. Such statements are based on management’s
current expectations, but actual results may differ materially due to various factions including those
risks and uncertainties mentioned or referred to in this press release. Accordingly, you should not rely
on those forward-looking statements as a prediction of actual future results.



Contacts:

USA:
Vivian Chen
Grayling
T: +1 646-284-9472
Vivian.Chen@grayling.com



Australia: Investor Relations
Rebecca Wilson
T: +61 3 8866 1216
E: rwilson@buchanwe.com.au



Media Relations
Ben Oliver
T: +61 3 8866 1233
E: boliver@buchanwe.com.au
www.pranabio.com/downloads/...bal%20neuroscience%20project.pdf

RTK 5,66  $ RTP -0,35 EK 5,68 $ last shares 500 full reltime 99.675 peak 5,80

buran und MfG und sowieso und überhaupt und weitermachen und lass krachen

Datum Erster Hoch Tief Schluss     Stücke Volumen
  04.12.13      5,80      5,80§5,56 5,79 $ 324.005 1,84 M

..solange die schöne PRANA inne Depots reinpasst ..wird keene Arbeit anjefasst ..schrumm schrumm schrumm ..wer nch ordert der iss dumm ..diedelbumm ..bumm ..bumm

buran & PRANA,Die Börsen Sissi Tausendschönsten

       100          §
  15:51:42§5,68 $
       100          §
  15:51:37§5,681 $
     1.500          §
  15:50:46§5,69 $
       275          §
  15:49:12§5,69 $
       500          §
  15:49:12§5,73 $
       500          §
  15:47:02§5,71 $
       100          §
  15:47:02§5,71 $
       100          §
  15:46:37§5,7199 $
       100          §
  15:46:16§5,7062 $
       300          §
  15:45:59§5,70 $
       452          §
  15:45:58§5,7101 $
       100          §
  15:45:58§5,71 $
       100          §
  15:45:56§5,71 $
       100          §
  15:45:55§5,70 $
       298          §
  15:45:55§5,70 $
       250          §
  15:44:40§5,701 $
       300          §
  15:44:40§5,701 $
       290          §
  15:44:40§5,701 $
       300          §
  15:44:40§5,72 $
     2.000          §
  15:44:40§5,72 $
       500          §
  15:44:40§5,72 $
     1.000          §
  15:44:21§5,721 $
       100          §
  15:44:20§5,721 $
       900          §
  15:44:19§5,721 $
     1.000          §
  15:44:12§5,72 $
       100          §
  15:44:11§5,74 $
       100          §
  15:44:11§5,72 $
       800          §
  15:44:11§5,74 $
       100          §
  15:43:29§5,7402 $
       300          §
  15:43:03§5,741 $
       712          §
  15:43:02§5,76 $
       700          §
  15:43:02§5,78 $
       200          §
  15:43:02§5,77 $
       200          §
  15:41:40§5,7999 $
     1.000          §
  15:39:38§5,8199 $
       500          §
  15:38:58§5,81 $
       100          §
  15:38:54§5,82 $
     1.000          §
  15:38:40§5,82 $
       100          §
  15:38:37§5,82 $
       400          §
  15:37:38§5,76 $
       200          §
  15:37:37§5,7601 $
       200          §
  15:37:37§5,79 $
     1.600          §
  15:37:14§5,761 $
     2.500          §
  15:36:22§5,7799 $
       800          §
  15:36:20§5,78 $
       369          §
  15:35:50§5,77 $
       100          §
  15:35:47§5,7603 $
       500          §
  15:35:42§5,78 $
       500          §
  15:35:34§5,79 $
     1.800          §
  15:35:31§5,79 $
       200          §
  15:35:30§5,80 $
     1.825          §
  15:35:19§5,80 $
       100          §
  15:35:19§5,8001 $
       700          §
  15:35:19§5,80 $
       100          §
  15:35:19§5,8001 $
       300          §
  15:35:13§5,81 $
       100          §
  15:35:11§5,8101 $
       187          §
  15:35:10§5,82 $
       678          §
  15:34:51§5,82 $
     3.500          §
  15:34:51§5,85 $
     5.040          §
  15:34:51§5,86 $
     1.500          §
  15:34:32§5,86 $
     1.000          §
  15:34:18§5,8799 $
       200          §
  15:34:09§5,88 $
       100          §
  15:34:07§5,88 $
       100          §
  15:33:59§5,8701 $
       400          §
  15:33:59§5,88 $
       600          §
  15:33:51§5,85 $
     5.000          §
  15:33:28§5,85 $
       600          §
  15:33:28§5,86 $
       200          §
  15:33:28§5,85 $
       200          §
  15:33:25§5,89 $
       100          §
  15:33:25§5,88 $
       580          §
  15:33:22§5,85 $
     1.060          §
  15:33:19§5,85 $
       100          §
  15:33:18§5,85 $
       500          §
  15:33:16§5,85 $
       600          §
  15:33:12§5,8499 $
       100          §
  15:33:12§5,85 $
       100          §
  15:32:49§5,85 $
       600          §
  15:31:00§5,8201 $
     2.000          §
  15:30:40§5,8499 $
       500          §
  15:30:40§5,85 $
       500          §
  15:30:09§5,84 $
     1.000          §
  15:30:00§5,83 $
1.476

GrB

Datum Erster Hoch Tief Schluss     Stücke Volumen
  05.12.13      5,83      5,89§5,45 5,70 $ 348.601 1,83 M

GrB

:::::::::::::: 5,71 $ +0,18% +0,01 $
In Euro: 4,1667 € | Nasdaq, 06.12.13 ,GrB

Datum Erster Hoch Tief Schluss     Stücke Volumen
  06.12.13      5,70      5,76§5,50 5,71 $ 193.623 1,09 M

..Aktien mögen sowas ..Haut so weiss wie Elfenbein ..das Haar so schwarz wie Ebenholz ..Lippen süsser als roter Wein ..nie hab ich schöneres gesehen ..sagt wer ist das holde Kind ..das kann nur meine schöne PRANA sein ..ei fei ..;o) ..nuff ..tüff .tüff

buran & PRANA,Das Börsen Liebesnest Molkereiweg 23

Bist noch drin? Habe mir heute eine kleine Position gegönnt. Das scheint hier sehr erfolgversprechend zu sein.
Der Alzheimerspezialist mit einer MK gerade mal von 285 Mio USD läuft doch noch bis mindestens 500.Nach dann, viel Erfolg allen Investierten!

Datum Erster Hoch Tief Schluss     Stücke Volumen
  15.01.14      6,26      6,40§6,251 6,34 $ 183.177 1,13 M
  14.01.14      6,29      6,47§6,02 6,27 $ 316.066 1,95 M
  13.01.14      6,05      6,50§6,01 6,22 $ 568.481 3,46 M
  10.01.14      6,02      6,47§6,02 6,28 $ 537.849 3,31 M
  09.01.14      6,28      6,28§5,86 6,02 $ 593.139 3,49 M
  08.01.14      6,13      6,31§6,10 6,24 $ 330.737 2,02 M
  07.01.14      6,01      6,36§5,83 6,22 $ 1.188.693 6,94 M
  06.01.14      6,80    6,8199§6,23 6,27 $ 1.051.681 6,71 M
  03.01.14      7,05      7,05§6,86 6,99 $ 218.326 1,49 M
  02.01.14      6,99      7,15§6,85 7,03 $ 283.638 1,95 M

GrB

Datum Erster Hoch Tief Schluss     Stücke Volumen
  17.01.14      6,94    7,4435§6,75 7,10 $ 952.413 6,64 M

GrB

PRANA BIOTECHNOLOGY LTD Aktie
WKN: 753907 Symbol: PRAN Typ: Aktie
SK 7,10 $ SKP +0,00 Pott +55,34%

buran und MfG und schüddelböööööön

  16.01.14      6,24      7,09§6,20 6,93 $ 751.323 5,00 M
  15.01.14      6,26      6,40§6,251 6,34 $ 183.177 1,13 M
  14.01.14      6,29      6,47§6,02 6,27 $ 316.066 1,95 M
  13.01.14      6,05      6,50§6,01 6,22 $ 568.481 3,46 M
  10.01.14      6,02      6,47§6,02 6,28 $ 537.849 3,31 M
  09.01.14      6,28      6,28§5,86 6,02 $ 593.139 3,49 M
  08.01.14      6,13      6,31§6,10 6,24 $ 330.737 2,02 M
  07.01.14      6,01      6,36§5,83 6,22 $ 1.188.693 6,94 M
  06.01.14      6,80    6,8199§6,23 6,27 $ 1.051.681 6,71 M
  03.01.14      7,05      7,05§6,86 6,99 $ 218.326 1,49 M
  02.01.14      6,99      7,15§6,85 7,03 $ 283.638 1,95 M

GrB

Was war das denn zum Schluss? Oder man ist eben schon verwöhnt. Waren sehr gute Tage!

Datum Erster Hoch Tief Schluss     Stücke Volumen
  06.02.14     11,89     12,12§10,65 10,88 $ 1.086.354 12,0 M

GrB

Prana Biotechnology Ltd Could Be Big Movers in Healthcare Todaywww.fool.com/investing/general/2014/01/31/...nc-and-prana.aspx

Jan. 24 to Jan. 31
Comment NowFollow Comments
These are the best and worst-performing medical and biotech stocks from Jan. 24 to Jan. 31, a period during which the American Stock Exchange’s Biotechnology Index r0se 0.4%. This screen includes biotechnology and medical companies traded on the New York Stock Exchange, the Nasdaq or the American Stock Exchange that had market capitalizations of more than $300 million at the beginning of the week. The data come from Interactive Data and Thomson Reuters Fundamentals via FactSet Research Systems.www.forbes.com/sites/matthewherper/2014/02/...partner=yahootix

It Sounds
Feb. 3, 2014 9:12 AM ET | seekingalpha.com/article/...icious-than-it-sounds?source=yahoo

Number of Tickers: 245
Date: 6-Feb-14
Contributor:§ValuEngine, Inc.
    Title:§ValuEngine Industry Report for Medical-biomed/genetics
Document Size: 18 pages
Price: $49
Document Type: Adobe Acrobat Reader®
Download free Adobe Acrobat Reader®
reports.finance.yahoo.com/w0?r=50217056:1

SK 10,88 $ SKP -7,40 Pott +137,08% buran und MfG und danke und Die schöne PRANA

Top!! Bist heut bisschen aufgestiegen;-) n'kleines bisschen!
Wer den Aktien ab und an mal Komplimente macht, dann siehsts so aus wie Hier!
Was meinste? Wieviel ist hier noch möglich?  

Die müsste wohl nachziehen, oder lieg ich da falsch?

Kann mir evtl. jemand den unterschied zwischen Prana 937103 und Prana 753907 erkären?
Finde zu WKN 937103 nirgends ein Info.
Danke

Das sind im Grunde die gleichen, nur für den Amerikanischen Handel in Verhäntnis 10:1

Viele Firmen machen das so, zb. Vestas Windsystem da ist das Verhältnis 3:1

Solche Aktien erkennt an deren Endungszusatz

Ltd.Shares = Firmenanteile

Spon         = gesplittet

"In addition, the results indicated a significant benefit on cognition that is consistent with the previous trial in Alzheimer's disease and is accompanied by an encouraging finding in functional capacity. We are very thankful for the involvement of the research participants and investigators in this study and look forward to future trials of this promising therapy for one of the cardinal features of Huntington disease."

Reach2HD is a double-blind, placebo-controlled study was conducted by the Huntington Study Group at research sites in the United States and Australia. The study enrolled 109 individuals with Huntington disease who were randomly assigned to receive daily doses of either PBT2 250mg, PBT2 100mg, or placebo for 26 weeks.

The primary endpoint of the study was met. In this study, PBT2 was safe and well tolerated. Ninety-five percent (104 of 109) of participants completed the study on their assigned dose. There were no substantial differences in adverse events across the two PBT2 dose groups and the placebo group. Only one of the ten reported serious adverse events was deemed by the clinical site investigator to be related to drug treatment.

An independent Data Safety Monitoring Board met on five occasions over the course of the trial and on each occasion recommended that the trial continue as per the original protocol.

The effects of PBT2 were tested on cognition, motor performance, behaviour and functional capacity, of which cognition was pre-specified as the main efficacy outcome.

There was a statistically significant improvement in performance on the Trail Making Test Part B, in the PBT2 250mg group compared to placebo at both 12 (p<0.001) and 26 weeks (p=0.042). Trail Making Test Part B is a measure of executive function (e.g., ability to plan activities), which is impaired early in the course of Huntington disease and is also affected in Alzheimer's disease.

Given the evidence from an earlier trial that showed that PBT2 improved executive function in Alzheimer's disease patients, the Reach2HD trial included a plan to assess the effects of PBT2 on an Executive Function Composite z-score that included the Trail Making Test Part B. There was a statistically significant improvement in this z-score (p=0.038) in a pre-specified analysis of Reach2HD participants with early stage Huntington disease, as measured by their Total Functioning Capacity score. Across all participants, which comprised both early and mid-stage patients, there was a trend to improvement (p=0.069).

Dr. Rudy Tanzi, Professor of Neurology at Harvard Medical School and Prana's Chief Scientific Advisor, said: "The observation of significant improvement in executive function with PBT2 in this clinical trial for Huntington disease and the previously reported Alzheimer's trial, suggests a common mechanism for neurodegeneration in these diseases based on metal interactions. In my opinion, these findings significantly elevate the potential for PBT2 as an effective therapy for both Huntington disease and Alzheimer's disease."

The improvement in executive function was accompanied by a small but favourable signal in a key measure of functional capacity.

Dr. Ira Shoulson, Professor of Neurology at Georgetown University and Chair of the Huntington Study Group, who was not involved in the trial and acts as an advisor to Prana, added: "In the Reach2HD trial, the improvement in executive function performance was also accompanied by a favourable signal of a slowing of functional decline, as measured by the Total Functional Capacity score. This is the first time we have observed dose-related slowing in functional decline over a six month period of treatment – which taken together with the safety reassurance –  will provide genuine optimism for the Huntington disease community to support a larger confirmatory trial of PBT2 in Huntington disease."

Finally, as Huntington disease and other neurodegenerative disorders progress, there is a gradual loss of brain tissue or atrophy. In Reach2HD, brain imaging using magnetic resonance imaging (MRI) was performed in a small subset of patients (n=6) to map anatomical changes in brain structure. In the combined PBT2 groups (n=4) a reduction in atrophy  of brain tissue in regions of the brain known to be affected by Huntington disease was observed compared to the placebo group.

Dr. Diana Rosas, Associate Professor of Neurology at Harvard Medical School and the study's co-Principal Investigator who conducted the imaging sub-study commented: "Despite the very small number of patients in the sub-study, the data are suggestive of a beneficial effect of PBT2 in regions of the brain that are known to be vulnerable to Huntington disease."

A detailed clinical announcement is available on the Company's web site at www.pranabio.com. For patient enquiries please contact huntingtons@pranabio.com or call 1300 13 90 33.

Investor Conference Call Information:

Prana will host an investor conference call and webcast this evening at 5:30pm Eastern Time to discuss the study results.  Investors in the United States may access the conference call by dialing 1 (855) 293-1544; conference ID: 58817510.  The live webcast may be accessed here.  Additional conference call information is available at www.pranabio.com, including Australian and international conference numbers.

Due to the expected high number of participants on the call, we recommend you commence registration for the event 15 minutes prior.   A recording of the call will be available within 4 hours of its conclusion and will remain available for three months.  The archived recording can be accessed here.

Contacts:



Global Investor Relations Lead

Rebecca Wilson

T: +61 3 8866 1216

E: rwilson@buchanwe.com.au

Investor Relations (USA)

Joshua Drumm

T: +1 (212) 375-2664

E: jdrumm@tiberend.com






Media Relations (Australia)

Ben Oliver

T: +61 3 8866 1233

E: boliver@buchanwe.com.au

Media Relations (US)

Andrew Mielach

T: +1 (212) 375-2694

E: amielach@tiberend.com





SOURCE Tiberend Strategic Advisors, Inc.


Quelle: PR Newswire

  13.02.14      7,89      8,78§7,89 8,14 $ 1.374.408 11,2 M
  12.02.14      8,69      8,74§7,90 8,03 $ 1.980.311 15,8 M
  11.02.14      9,33      9,55§8,55 8,69 $ 1.415.328 12,4 M
  10.02.14      9,35      9,73§8,26 9,14 $ 3.793.439 32,6 M
  07.02.14     10,40     10,93§9,51 9,92 $ 1.999.607 19,8 M
  06.02.14     11,89     12,12§10,65 10,88 $ 1.086.354 12,0 M
  05.02.14     11,74   12,3199§11,35 11,75 $ 814.071 9,21 M
  04.02.14     11,50     12,50§11,41 11,77 $ 1.329.920 15,3 M
  03.02.14     11,28     11,85§10,46 11,24 $ 1.709.203 18,5 M

buran und MfG und danke und weitermachen

Datum Erster Hoch Tief Schluss     Stücke Volumen
21.03.14 7,483 8,15 7,483  8,15 € 1.000 8.150

buran

Datum Erster Hoch Tief Schluss     Stücke Volumen
21.03.14 11,07 11,44 10,73  10,79 $ 1.635.882 17,7 M

buran und MfG und danke und weitermachen und TOP

No improvement was observed on the secondary endpoints of brain metabolic activity, cognition and function; however there was a trend towards preserving hippocampal brain volume in the PBT2 group.  Specifically, there was less atrophy in those patients treated with PBT2 relative to placebo, 2.6% and 4.0%, respectively.  This is consistent with published measures of atrophy in AD patients versus healthy controls2 of 4.7% and 1.4%, respectively. The company is tracking measures of brain volume and cognition in the current 12 month extension study that will be completed at the end of the year. Further analysis of the results is ongoing.

Importantly, PBT2 was shown to be safe and very well tolerated over the 52 weeks. The adverse event profile was equivalent between placebo and treated groups. Forty of the 42 enrolled participants (95%) completed the 52 week treatment period.

Mr. Kempler concluded: "Whilst not meeting all of our hopes, this result does not deter us from the future development of PBT2, a safe and well tolerated drug candidate for Alzheimer's disease. Our scientists and those from other institutes have developed a strong body of evidence for the efficacy of PBT2 in Alzheimer's disease. The suggestion of beneficial effect of PBT2 on brain volumes first seen in the Reach2HD Huntington disease trial and now in this Alzheimer's disease IMAGINE trial is intriguing. We are consulting with experts in the field to further assess these results and to consider how best to progress PBT2 in Alzheimer's disease. Indeed, the IMAGINE Extension trial is continuing, and data from this trial is likely to inform the next steps for an AD program."

Prana is proceeding with its plans toward a confirmatory study for Huntington disease.  Based on Prana's previous discussion with the US Food and Drug Administration, the data on safety and tolerability of PBT2 in Alzheimer's disease will support the future clinical development and, ultimately, a New Drug Application in Huntington disease.

Prana has a cash position of AU$25.4 million as at 31 March 2014.

1.  Lannfelt et al. Lancet Neurology (2008) vol. 7, pp. 779-86; Lannfelt et al. Lancet Neurology (2009) vol. 8, pp. 981.

2.  Barnes et al. Neurobiology of Aging (2009) 1711-1723

Investor conference call

Prana is hosting an investor conference call at 11.00pm Australian Eastern Daylight Savings time on Monday 31st March (8.00am USA EDT; 5.00am USA PDT, and 1.00pm UK BST).

The conference call will be recorded and available from 1am Australian EDST, Tuesday 1 April, at www.openbriefing.com/OB/1378.aspx

Conference ID: 693727



Australian Participation Dial-in-numbers

Toll: +61 2 9007 3187 (can be used if dialing from an international location)

Toll-free: 1800 558 698

Toll-free: 1800 809 971

International Participation Dial-in-numbers

Canada/USA Toll Free:                1855 881 1339

New York Local Number              208 758 0667

France Toll Free:                        0800 913 848

Germany Toll Free:                     0800 182 7617

Hong Kong Toll Free:                  800 966 806

New Zealand Toll Free:               0800 453 055

Singapore Toll Free:                   800 101 2785

South Africa Toll Free:                0800 999 976

Switzerland Toll Free:                 0800 820 030

United Kingdom Toll Free:           0800 051 8245

Contacts:



Global Investor Relations Lead                                

Investor Relations (USA)

Rebecca Wilson                                              

Joshua Drumm

T: +61 3 9866 4722                                          

T: +1 212-375-2664

E: rwilson@buchanwe.com.au                  

E: jdrumm@tiberend.com





Media Relations (Australia)                  

Media Relations (US)

Ben Oliver                                                          

Andrew Meilach

T: +61 3 9866 4722                                          

T: +1 212-375-2694

E: boliver@buchanwe.com.au                  

E: amielach@tiberend.com

About Prana Biotechnology Limited

Prana Biotechnology was established to commercialise research into Alzheimer's disease and other major age-related neurodegenerative disorders. The Company was incorporated in 1997 and listed on the Australian Stock Exchange in March 2000 and listed on NASDAQ in September 2002.  Researchers at prominent international institutions including The University of Melbourne, The Mental Health Research Institute (Melbourne) and Massachusetts General Hospital, a teaching hospital of Harvard Medical School, contributed to the discovery of Prana's technology.

About IMAGINE Phase II Clinical Trial for Alzheimer's Disease

A randomized placebo-controlled clinical study involving 42 patients (males and females over 44 years) with prodromal or mild Alzheimer's disease. Patients were randomized (ratio of 2:1) into either an active treatment group receiving 250mg PBT2 or placebo group over 52 weeks.  The primary objective was to evaluate brain amyloid levels by PiB PET imaging. The secondary objective was to evaluate the effect of PBT2 on safety and tolerability, brain metabolic activity, brain volumes and cognition, and functional abilities.    




Forward Looking Statements

This press release contains "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934.  The Company has tried to identify such forward-looking statements by use of such words as "expects," "intends," "hopes," "anticipates," "believes," "could," "may," "evidences" and "estimates," and other similar expressions, but these words are not the exclusive means of identifying such statements.  Such statements include, but are not limited to any statements relating to the Company's drug development program, including, but not limited to the initiation, progress and outcomes of clinical trials of the Company's drug development program, including, but not limited to, PBT2, and any other statements that are not historical facts.  Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to the difficulties or delays in financing, development, testing, regulatory approval, production and marketing of the Company's drug components, including, but not limited to, PBT2, the ability of the Company to procure additional future sources of financing, unexpected adverse side effects or inadequate therapeutic efficacy of the Company's drug compounds, including, but not limited to, PBT2, that could slow or prevent products coming to market, the uncertainty of patent protection for the Company's intellectual property or trade secrets, including, but not limited to, the intellectual property relating to PBT2, and other  risks detailed from time to time in the filings the Company makes with Securities and Exchange Commission including its annual reports on Form 20-F and its reports on Form 6-K.  Such statements are based on management's current expectations, but actual results may differ materially due to various factions including those risks and uncertainties mentioned or referred to in this press release.  Accordingly, you should not rely on those forward-looking statements as a prediction of actual future results.

SOURCE Prana Biotechnology Limited


Quelle: PR Newswire

Prana Biotechnology CEO and Executive Chairman Geoffrey Kempler said: "Professor Shoulson's clinical and regulatory experience will be pivotal as Prana prepares to meet with regulators later this year to chart the next steps in PBT2's development as a treatment for Huntington disease."

Professor Shoulson said joining the Prana board was an exceptional opportunity to help develop the next generation of treatments for neurodegenerative disorders.

"I have spent my entire professional life developing treatments aimed at making a difference for patients with Huntington disease, Parkinson disease and similar neurodegenerative disorders," he said.

"Based on the Reach2HD study and ongoing discovery and translational research, I believe PBT2 is among the most promising of experimental treatments intended to ameliorate the disabling cognitive impairment of HD, which is a major source of disability for our patients."

"Besides PBT2, Prana has an expanding library of compounds that are applicable not just to neurological disorders but other disorders including cancer."

Professor Shoulson's position as a non-Executive Director of Prana Biotechnology is effective immediately. Prior to taking up his position with Prana, Professor Shoulson concluded his elected term as Chair and President of the Huntington Study Group.

Contacts:







Investor Relations          

Media Relations

Rebecca Wilson            

Ben Oliver                        

T: +61 3 8866 1216        

T: +61 3 8866 1233          

E: rwilson@buchanwe.com.au    

E: boliver@buchanwe.com.au                  

About Prana Biotechnology Limited

Prana Biotechnology was established to commercialise research into Alzheimer's disease, Huntington disease and other neurodegenerative and movement disorders. The Company was incorporated in 1997 and listed on the Australian Stock Exchange in March 2000 and listed on NASDAQ in September 2002.  Researchers at prominent international institutions including The University of Melbourne, The Mental Health Research Institute (Melbourne) and Massachusetts General Hospital, a teaching hospital of Harvard Medical School, contributed to the discovery of Prana's technology.

Forward Looking Statements

This press release contains "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934.  The Company has tried to identify such forward-looking statements by use of such words as "expects," "intends," "hopes," "anticipates," "believes," "could," "may," "evidences" and "estimates," and other similar expressions, but these words are not the exclusive means of identifying such statements.  Such statements include, but are not limited to any statements relating to the Company's drug development program, including, but not limited to the initiation, progress and outcomes of clinical trials of the Company's drug development program, including, but not limited to, PBT2, and any other statements that are not historical facts.  Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to the difficulties or delays in financing, development, testing, regulatory approval, production and marketing of the Company's drug components, including, but not limited to, PBT2, the ability of the Company to procure additional future sources of financing, unexpected adverse side effects or inadequate therapeutic efficacy of the Company's drug compounds, including, but not limited to, PBT2, that could slow or prevent products coming to market, the uncertainty of patent protection for the Company's intellectual property or trade secrets, including, but not limited to, the intellectual property relating to PBT2, and other  risks detailed from time to time in the filings the Company makes with Securities and Exchange Commission including its annual reports on Form 20-F and its reports on Form 6-K.  Such statements are based on management's current expectations, but actual results may differ materially due to various factions including those risks and uncertainties mentioned or referred to in this press release.  Accordingly, you should not rely on those forward-looking statements as a prediction of actual future results.

SOURCE Prana Biotechnology


Quelle: PR Newswire

Wenn man das US Board liest könnte es hier abgehen. Bin ich gespannt mit meinem Long Investment.

Nur meine Meinung, keine Kauf- oder Verkaufsempfehlung.

www.nasdaq.com/symbol/pran/premarket

Pre 50000 Stk a 2.12 :-)

www.nasdaq.com/symbol/pran/real-time

Ist was im Busch?

www.nasdaq.com/symbol/pran/real-time

Ziemlich nett!

Prana ist nur geil... Die geht gleich mal durch die Decke

Denke hier geht noch einiges die nächsten Wochen m.M.n!

www.asx.com.au/asxpdf/20140717/pdf/42qw7rf876c35j.pdf

Das sieht ziemlich gut aus. Mal sehen, ob das hält und die Leute verstehen, dass das Stoppen der Gehirnschrumpfung ein positiver Wahnsinn ist :-)

In Professor Masters' presentation, he noted that the starting amyloid burden level (baseline) in the PBT2 treated participant group had an important bearing on the decrease of amyloid over time in that participant (p=0.035), whereas there was no such correlation in the placebo group.

Prof Masters further investigated the response of participants with baseline amyloid burden levels above and below the mean for the IMAGINE cohort (SUVR of 2.5). He showed that in the subgroup of PBT2 treated participants with a baseline of SUVR above 2.5, there was a significant decrease in amyloid burden that was not observed in participants on placebo nor PBT2 participants with a SUVR less than 2.5. In summary, whilst the utility of PiB in small trials may be questioned, it was interesting to note the impact of baseline SUVR amyloid burden level on the response of a cohort, for future trial design.

Separately, Prana has confirmed the top line finding that there is a very promising trend towards the preservation of brain volume (as measured by MRI) in PBT2 treated patients compared to placebo patients.

Mechanism of action of PBT2 in AD  

PBT2 prevents formation and toxicity of pathological ABeta species (primarily soluble oligomers) and promotes their clearance. In Professor Masters' presentation he proposes the observed effect upon amyloid burden is due to increased clearance by PBT2 of pools of PIB-detectable non-fibrillar soluble and membrane bound ABeta.

Through its metal chaperone activity, PBT2 activates intracellular signalling pathways which promote neuronal health and plasticity and suppress pathobiological processes including the abnormal phosphorylation of tau. The trend towards reduced hippocampal atrophy seen in the PBT2 treatment group mirrors the Company's preclinical observations and reinforces a similar trend observed in the Reach2HD Huntington's disease study.

"Understanding the limitations of a small trial, the atypical placebo group response, previous clinical findings (the EURO trial), the strong body of peer reviewed science, along with the sub-analyses of IMAGINE, the company remains enthusiastic about the prospects of a large trial statistically powered to demonstrate cognitive benefit," Prof. Masters said.

IMAGINE EXTENSION TRIAL UPDATE  

Patients who completed the full 12-month term of the IMAGINE trial were eligible for participation in an open-label Extension study. All participants in the Extension study receive a 250mg once daily oral dose of PBT2 for an additional 12 months during which PiB-PET and MRI imaging will continue.

Thirty three patients elected to join the Extension trial and of these, 30 remain on the trial. Of those participants, 21 have now been identified as being randomized to the PBT2 treatment arm in the IMAGINE study. Of these, all 21 patients have completed 14 months of PBT2 administration, 20 have completed 18 months of PBT2 administration and nine have completed 21 months of PBT2 administration.

We are very pleased with the continuing safety profile of the drug. The data safety monitoring board has met a further two times and has not expressed any concerns in relation to adverse events.

Contacts:  

Investor Relations  

Rebecca Wilson,? T: +61 3 8866 1216, ?E: rwilson@buchanwe.com.au

Media Relations  

Ben Oliver, ?T: +61 3 8866 1233?, E: boliver@buchanwe.com.au

About Prana Biotechnology Limited  

Prana Biotechnology was established to commercialise research into Alzheimer's disease, Huntington disease and other neurodegenerative and movement disorders. The Company was incorporated in 1997 and listed on the Australian Stock Exchange in March 2000 and listed on NASDAQ in September 2002. Researchers at prominent international institutions including The University of Melbourne, The Mental Health Research Institute (Melbourne) and Massachusetts General Hospital, a teaching hospital of Harvard Medical School, contributed to the discovery of Prana's technology.

Forward Looking Statements  

This press release contains "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934. The Company has tried to identify such forward-looking statements by use of such words as "expects," "intends," "hopes," "anticipates," "believes," "could," "may," "evidences" and "estimates," and other similar expressions, but these words are not the exclusive means of identifying such statements. Such statements include, but are not limited to any statements relating to the Company's drug development program, including, but not limited to the initiation, progress and outcomes of clinical trials of the Company's drug development program, including, but not limited to, PBT2, and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to the difficulties or delays in financing, development, testing, regulatory approval, production and marketing of the Company's drug components, including, but not limited to, PBT2, the ability of the Company to procure additional future sources of financing, unexpected adverse side effects or inadequate therapeutic efficacy of the Company's drug compounds, including, but not limited to, PBT2, that could slow or prevent products coming to market, the uncertainty of patent protection for the Company's intellectual property or trade secrets, including, but not limited to, the intellectual property relating to PBT2, and other risks detailed from time to time in the filings the Company makes with Securities and Exchange Commission including its annual reports on Form 20-F and its reports on Form 6-K. Such statements are based on management's current expectations, but actual results may differ materially due to various factions including those risks and uncertainties mentioned or referred to in this press release. Accordingly, you should not rely on those forward-looking statements as a prediction of actual future results.

SOURCE Prana Biotechnology


Quelle: PR Newswire

Da kommt vielleicht bald eine Nachricht, weiß jemand vielleicht was anstehen könnte?

www.nasdaq.com/symbol/pran/premarket

In FWB +45%

USA yesterday 2,14 , aktuelles Bid/Ask PreMarket 2,67/2,85...

Da müssen noch News kommen....

www.proactiveinvestors.com.au/companies/...ignation-57400.html

wieder aufgehoben an der asx ?

www.asx.com.au/asxpdf/20140905/pdf/42s113r97q6gr0.pdf

Datum Erster Hoch Tief Schluss     Stücke Volumen
  19.09.14      2,12      2,24§2,09 2,12 $ 859.793 1,85 M

GrB

seekingalpha.com/news/...on-als-drug-shows-encouraging-results

buran: nur ein börsenboard geführt von www.bundesbank.de 21:18 #1
achte er einfach auf die links
Mit freundlichen Grüssen Mario Meierhof 39517 Lüderitz Gartenstrasse 6
mariomeierhof@web.de
Tel.:039361/96548 Atelier Meierhof 039361/51273 Kuhle
gez MARIO alias buran http://www.ariva.de/…/nur-ein-boersenboard-gefuehrt-von-www…

Deutsche Bundesbank - Startseite
Die Deutsche Bundesbank ist die Zentralbank der Bundesrepublik Deutschland. Zentrales Geschäftsfeld ist die Geldpolitik des Eurosystems.
BUNDESBANK.DE
https://www.facebook.com/mario.meierhof

buran: auch ich war im Erziehungsheim lange eine Ewigkeit 228.10.14 20:01 #1
Mario Meierhof
29. September um 21:38 ·
buran: nur ein börsenboard geführt von www.bundesbank.de 21:18 #1
achte er einfach auf die links
Mit freundlichen Grüssen Mario Meierhof 39517 Lüderitz Gartenstrasse 6
mariomeierhof@web.de
Tel.:039361/96548 Atelier Meierhof 039361/51273 Kuhle
gez MARIO alias buran http://www.ariva.de/…/nur-ein-boersenboard-gefuehrt-von-www…

Deutsche Bundesbank - Startseite
Die Deutsche Bundesbank ist die Zentralbank der Bundesrepublik Deutschland. Zentrales Geschäftsfeld ist die Geldpolitik des Eurosystems.
BUNDESBANK.DE
https://www.facebook.com/mario.meierhof
http://www.ariva.de/forum/...rziehungsheim-lange-eine-Ewigkeit-510117

buran: Kontakt   01.10.14 21:33 #1 Inhalt
Haben Sie Fragen oder Anmerkungen?
Dann nutzen Sie unser Kontaktformular, um uns eine Nachricht zukommen zu lassen.
Als Medienvertreter nutzen Sie bitte die Seite cvd.bundesregierung.de.
Felder mit einem * sind Pflichtfelder und müssen ausgefüllt werden.
Selbstverständlich beachten wir die Vorschriften des Datenschutzes.
Hier geht es zur Datenschutzerklärung.

Betreff * Hallo ,vielleicht sowas mal unterbinden wäre nett


Ihre Anregungen und Fragen (max. 10.000 Zeichen) *noch 9663 Zeichen nur ein börsenboard geführt von www.bundesbank.de
achte er einfach auf die links

Mit freundlichen Grüssen Mario Meierhof 39517 Lüderitz Gartenstrasse 6
mariomeierhof@web.de
Tel.:039361/96548 Atelier Meierhof 039361/51273 Kuhle

gez MARIO alias buran http://www.ariva.de/forum/...rd-gefuehrt-von-www-bundesbank-de-508523


Vor- und Zuname * Mario Meierhof

E-Mail *mariomeierhof@web.de


Straße und Hausnummer Gartenstrasse 6

Postleitzahl 39517

Ort Lüderitz

* Pflichtangabe
https://www.bundesregierung.de/Webs/Breg/DE/.../kontaktform_node.html

Mit freundlichen Grüssen Mario Meierhof alias buran
http://www.ariva.de/forum/Kontakt-508620?new_pnr=18779196#bottom

Irgendwie sieht das für Morgen ziemlich gut aus.

Ich bleib mit 6.000 Stück drinnen.

GLTA

The Lancet Neurology publishes Prana ’s Huntington’s Disease Trial

www.asx.com.au/asxpdf/20141118/pdf/42tsmxr1yb24vr.pdf

www.thelancet.com/search/...urnalFromWhichSearchStarted=laneur

Die Präsenzbörse ist die klassische Form des Börsenhandels. Hierbei finden die Geschäftsabschlüsse auf dem Börsenparkett zwischen den Händlern im persönlichen Kontakt statt.  http://www.ariva.de/extras/lexikon.m?begriff=Praesenzboerse

Computerbörse
http://www.ariva.de/extras/lexikon.m?begriff=Praesenzboerse

Buch dazu
http://www.ariva.de/prana_biotechnology_ltd-aktie/...les?boerse_id=40 GrB

Gehts wieder rauf.
Solche Kurse muss man einfach zum Kauf nutzen.Prana war schon mal 1 Euro Wert danach auf ueber 10 Euro gestiegen,jetz wieder um 1 Euro wert.Hier wird der Kurs in ein paar Monate einige hundert Prozent machen.Schaut such den Langfrist Chart an.
Ich bin dabei,so ne Chance werde ich nutzen.

Gestern die Bodenbildung im leichten Plus. dürfte heute der Rebound anstehen.
Die Range 1,40-1,60 sollte wieder erreicht werden in den USA

Fazit nach 1Woche... Die Burschen generieren anscheinend Geld und schmeißen jeden Tag fleißig Aktien. Daher ist der anstehende Rebound auf langfristig ein Rohrkrepierer.
Also wieder Position auflösen, sicher ist sicher und auf Watch lieber setzen. Nicht das das Teil zum Pennystock mutiert.

-72,19%

:::::::::: 1,115 $ ,GrB

Hops:::Hops:::Hops

..Du
..Wir
..Er
..Sie
..Es
usw...........

PS: Schrottmüll in der Klappse, neee ???

zu 1,16 an der Nasdaq. Längere Bodenbildung um 1,07. Bevor mich Alzheimer und Parkinson ereilen soll PRAN bittschön die Medikamente auf dem Markt haben.
Kaufgrund war allerdings auch ein Artikel von gestern aus The Street von Jim Cramer. Da sperren die Amis die Öhrchen auf. Ausserdem gibt es kaum eine besser gemachte Homepage als die von PRANA. Der Jahresbericht 2014 auf über 100 perfekten PDF-Seiten, das hat mir gefallen.

www.thestreet.com/story/13074299/3/...e-for-big-breakouts.html

Datum Erster Hoch Tief Schluss     Stücke Volumen
  20.03.15      1,23      1,23§1,14 1,15 $ 968.618 1,12 M

GrB

Datum Erster Hoch Tief Schluss     Stücke Volumen
  20.03.15     1,104     1,118§1,104 1,118 € 2.500 2.795

GrB

http://www.ariva.de/dax-index/news GrB

14:00 21.03.15


Zehn Wochen lang ist der Dax von einem Rekordhoch zum nächsten geeilt. Aber damit dürfte jetzt erst mal Schluss sein. Auf welche Korrekturmarken der wichtigste deutsche Aktienindex nun fallen könnte. http://www.ariva.de/news/Dax-steht-vor-Verschnaufpause-5316886

buran

-68,52%

..yöah

GRINS ...

5 Wochen gewartet, jetzt wird's was, News!

zu faul zum Nachschauen? Also son bisschen Arbeit muss man sich schon selber machen für den Börsenerfolg.

au.finance.yahoo.com/news/...esignation-europe-032200612.html

der Bodenbildungsprozess abgeschlossen bei der schönen PRANA, Kurse unter 1,20 kaum noch drin charttechnisch gesehen...

... dümpelt nach wie vor bei MINUS 68% (seit Threaderöffnung) herum.
Toll, diese Buran'sche Schrott-Empfehlung, so what ...
:::pups:::
..yöah

Kurse unter 1,20 gehören der Vergangenheit an. Basta.

aber der Sektor ist im Fieber. PRAN profitiert. Bodenbildung abgeschlossen.

Getaucht auf 1,27, erhobenen Hauptes auf 1,46 gesprungen die schöne PRANA.
Starker Volumenanstieg auf 1,5 Millionen Shares....

wohin die Reise geht, nach oben ist ja viel Platz ^^

ebenso !!!
SCHROTT halt, "empfohlen" von Buran.

www.streetinsider.com/Corporate+News/...+Disease/10610230.html

Und der Wald steht still und schweiget...

:::::::::::::: 1,15 $ +1,77% +0,02 $
In Euro: 1,0347 € | Nasdaq, 02.07.15 ,GrB

Stehen irgendwann hier mal Daten an? Der down des Marktes sollte ja jetzt vorbei sein

:::::::::::: 0,85 $ 0,00% +0,00 $
In Euro: 0,7913 € | Nasdaq, 06.11.15 ,GrB

http://www.ariva.de/news/...eering-Group-AG-Veroeffentlichung-5591749 GrB

resplit?

Dividenden & Splits
  24.03.16§Reverse Split 6:1 ,GrB

Preis pro Schein 2,24 $ Schleife 100 spread 4,67% buran und MfG olee RT

Biotechnology invites investors unable to attend the Annual General Meeting to participate via teleconference. NOVEMBER 10, 2017 pranabio.com/news#.Wgi2VlvWzIU